anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
== Toxicity, storage, and deactivation == Cyanogen bromide can be stored under dry conditions at 2 to 8 °C for extended periods. Cyanogen bromide is volatile, and readily absorbed through the skin or gastrointestinal tract. Therefore, toxic exposure may occur by inhalation, physical contact, or ingestion. It is acutely toxic, causing a variety of nonspecific symptoms. Exposure to even small amounts may cause fatal injury. LD50 orally in rats is reported as 25–50 mg/kg. Cyanogen bromide was used as a chemical weapon in the World War I by Austro-Hungarian forces, either as benzene solution or mixture with 25% bromoacetone and 50% benzene. The recommended method to deactivate cyanogen bromide is with sodium hydroxide and bleach. The aqueous alkali hydroxide instantly hydrolyzes BrCN to alkali cyanide and bromide. The cyanide can then be oxidized by sodium or calcium hypochlorite to the less toxic cyanate ion. Deactivation is extremely exothermic and may be explosive.
== History == TMA-2 was first described in the scientific literature by Viktor Bruckner in 1933. Subsequently, Alexander Shulgin discovered the hallucinogenic effects of TMA-2 in 1962 and published them in 1964. The drug was later described in further detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
The first company to use such method is Evonik company in 2000. The enzyme Lipase-CalB in its immobilized state is actually used in other pharmaceutical applications for the production of Odanacatib, and Sofosbuvir.
Sources: en.wikipedia.org
Moreover, the element resembles bismuth and, more generally, the other p-block metals in its physical and chemical behaviour. On this basis some authors have argued that it is better classified as a metal than as a metalloid. On the other hand, selenium has some semiconducting properties in its most stable form (though it also has insulating allotropes) and it has been argued that it should be considered a metalloid – though this situation also holds for phosphorus, which is a much rarer inclusion among the metalloids.
CaCO3 → CaO + CO2 Acids liberate CO2 from most metal carbonates. Consequently, it may be obtained directly from natural carbon dioxide springs, where it is produced by the action of acidified water on limestone or dolomite. The reaction between hydrochloric acid and calcium carbonate (limestone or chalk) is shown below:
Type B: onset at age 20 or older and duration of less than 10 years. Type C: onset at age 10–19 or duration of 10–19 years. Type D: onset before age 10 or duration greater than 20 years. Type E: overt diabetes mellitus with calcified pelvic vessels. Type F: diabetic nephropathy. Type R: proliferative retinopathy. Type RF: retinopathy and nephropathy. Type H: ischemic heart disease. Type T: prior kidney transplant. An early age of onset or long-standing disease comes with greater risks, hence the first three subtypes. Two other sets of criteria are available to diagnose gestational diabetes, both based on blood-sugar levels. Criteria for diagnosis of gestational diabetes, using the 100-gram Glucose Tolerance Test, according to Carpenter and Coustan:
=== In cytoplasmatic actins === ACTB is a highly complex locus. A number of pseudogenes exist that are distributed throughout the genome, and its sequence contains six exons that can give rise to up to 21 different transcriptions by alternative splicing, which are known as the β-actins. Consistent with this complexity, its products are also found in a number of locations and they form part of a wide variety of processes (cytoskeleton, NuA4 histone-acyltransferase complex, cell nucleus) and in addition they are associated with the mechanisms of a great number of pathological processes (carcinomas, juvenile dystonia, infection mechanisms, nervous system malformations and tumour invasion, among others). A new form of actin has been discovered, kappa actin, which appears to substitute for β-actin in processes relating to tumours.
Sources: en.wikipedia.org
While the "ness team" began moving to Bawdsey, the Orfordness site remained in use. This proved useful during one demonstration when the new system recently completed at Bawdsey failed. The next day, Robert Hanbury-Brown and the new recruit Gerald Touch started up the Orfordness system and were able to run the demonstrations from there. The Orfordness site was not closed until 1937.
Attempts to contact by mail in the late 1890s failed. United Brothers of Friendship - Founded August 1, 1861, by young local students in day or night schools. In 1868, on the advice of their teacher, W.H. Gibson, the society reorganized. Many chapters were formed in Kentucky, and a statewide Grand Lodge was formed in 1871. After establishing chapters outside Kentucky a National Grand Lodge was formed. W.H. Gibson served as the first State Grand Master for five years and as National Grand Master for four years. Unofficial female auxiliaries were called the Sisters of Friendship until 1878 when the organization formed the official Sisters of the Mysterious Ten, organized in local Temples. In 1878 the Order had about 4,000 members. That was the year they decided to establish another auxiliary, the Knights of Friendship, based on the story of David and Jonathan. In 1892 the UBF had 100,000 members in 19 states and 2 territories with 30,000 in Missouri alone. It was known to be active in Kentucky, Missouri, Arkansas, Louisiana, Texas, Mississippi, Alabama, Tennessee, West Virginia, Virginia, the District of Columbia, Pennsylvania, New York, New Jersey, Michigan, Kansas, Colorado, Washington, Canada, the West Indies and Africa. While predominantly black, the order had white members. There was evidence that the Grand United Order of Odd Fellows had something to do with its founding. United Knights and Daughters of America - Headquartered in St. Louis, Missouri. Reportedly had many members in the Midwest. Attempts to contact the order in 1923 were unsuccessful.
=== Cytogenetics === Cytogenetics is the study of chromosomes and chromosome abnormalities. While cytogenetics historically relied on microscopy to analyze chromosomes, new molecular technologies such as array comparative genomic hybridization are now becoming widely used. Examples of chromosome abnormalities include aneuploidy, chromosomal rearrangements, and genomic deletion/duplication disorders.
=== Screening of DELs in cells === DNA-encoded libraries (DELs) have been adapted for screening in living cells to better reflect native biological conditions, specifically using Xenopus laevis oocytes. This approach, termed cellular Binder Trap Enrichment (cBTE), facilitates the identification of small-molecule ligands that bind to target proteins in a native cellular environment. In this method, the protein of interest (POI) is expressed in oocytes as a fusion with a "Prey" protein, such as carbonic anhydrase IX (CAIX). Simultaneously, a "Bait" molecule—comprising a known ligand for the Prey protein linked to a DNA strand—is introduced. Alongside the Bait, a DEL is co-injected into the oocytes. If a DEL member binds to the POI, it brings its attached DNA tag into the same molecular complex as the Bait DNA via the POI–Prey–Bait interaction. Following incubation, the oocytes are lysed, and the lysate is subjected to Binder Trap Enrichment (BTE) as described above. In essence, the DEL and Bait DNA are ligated in droplets, thus encoding the binding event. The ligated DNA is then amplified and subjected to high-throughput sequencing to identify the DEL members that interacted with the POI.
== See also == List of investigational drugs List of investigational generalized anxiety disorder drugs List of investigational panic disorder drugs List of investigational social anxiety disorder drugs List of investigational anxiety disorder drugs Ibogaine
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.